BCR and B-cell chronic lymphocytic leukemia: Having elucidated the differential effects of idelalisib and fostamatinib/ibrutinib on S1PR1 expression and function, we next investigated the effects of these BCR signaling inhibitors on the processes responsible for entry of CLL cells into lymph nodes.